Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
- Description:
Competitive fluorescent adenosine receptor antagonist
- Description:
Fluorescent A3 adenosine receptor antagonist
- Description:
Fluorescent β2 adrenoceptor antagonist
- Description:
Competitive fluorescent β2-adrenoceptor antagonist
- Description:
Fluorescent β2-adrenoceptor antagonist
- Description:
Fluorescent D1 dopamine receptor antagonist
- Description:
Fluorescent H1 histamine receptor antagonist
- Description:
Fluorescent H2 histamine receptor antagonist
- Description:
Fluorescent H3 histamine receptor antagonist
- Description:
Fluorescent M3 muscarinic receptor antagonist